Long-term drug treatment of obesity in a private practice setting

Obesity Research

Volumn 5, Issue 6, 1997, Pages 578-586

  Atkinson, Richard L ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Chronic therapy; Fenfluramine; Hyperlipoproteinemia; Hypertension; Phenterminc

Indexed keywords

ANOREXIGENIC AGENT; FENFLURAMINE; LIPID; PHENTERMINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; DRUG COMBINATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; OBESITY; PATIENT; PRIVATE PRACTICE;

ADOLESCENT; ADULT; APPETITE DEPRESSANTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; FENFLURAMINE; HUMANS; LIPIDS; MALE; MIDDLE AGED; OBESITY; PATIENT DROPOUTS; PHENTERMINE; PRIVATE PRACTICE;

EID: 0031266131     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1550-8528.1997.tb00579.x     Document Type: Article

References (15)

1. Abenhaini L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
2. Andersen T, Stokholm KH, Backer OG, Quaade F. Longterm (5-year) results after either horizontal gastroplasty or very-low calorie diet for morbid obesity. Int J Obes. 1988;12:277-284.
3. Atkinson RL, Hubbard VS. Report on the NIH workshop on pharmacologic treatment of obesity. Am J Clin Nutr. 1994;60:153-156.
4. Bouchard C, Perusse L. Genetics of obesity. Annu Rev Nutr. 1993;13:337-354.
5. Bouchard C, Perusse L. Current status of the human obesity gene map. Obes Res. 1996;4:81-90.
6. Bray GA. The risks and disadvantages of obesity. In: The Obese Patient. Philadelphia: WB Saunders; 1976;215-251.
7. Bray GA. Obesity - a state of reduced sympathetic activity and normal or high adrenal activity (the autonomic and adrenal hypothesis revisited). Int J Obes. 1990;14(Suppl 3):77-92.
8. Bray GA. Barriers to the treatment of obesity. Ann Intern Med. 1991;115:152-153.
9. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4:263-270.
10. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simmonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993;70:537-541.
11. Choban PS, Atkinson RL, Moore BJ, et al. Guidance for Treatment of Adult Obesity. Bethesda: Shape Up America!; 1996.
12. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155: 701-709.
13. Dhurandhar NV, Atkinson RL. Primary pulmonary hypertension with obesity drugs. N Engl J Med. 1997;336:511.
14. Glass AR, Burman KD, Dahms WT, Boehm TH. Endocrine function in human obesity. Metabolism. 1981;30:89-104.
15. Goldstein DJ, Potvin JH. Long-term weight loss: The effect of pharmacologic agents. Am J Clin Nutr. 1994;60:647-657.